Outcomes of patients with melanoma brain metastases treated with ipilimumab and nivolumab with or without upfront comprehensive stereotactic radiosurgery
In this retrospective study, upfront cSRS was more often used in patients with higher-risk MBM and was associated with improved intracranial control, although no significant survival benefit was observed. These findings suggest that starting ipi/nivo alone may be reasonable for lower-risk MBM, but prospective studies are needed to guide optimal integration of cSRS.
Authors
- Warren N. Floyd
- Subasree Srinivasan
- Ian E. McCutcheon (ORCID: https://orcid.org/0000-0002-1638-3400)
- S. Ferguson
- Isabella C. Glitza Oliva (ORCID: https://orcid.org/0000-0002-4530-7765)
- T. Kleber (ORCID: https://orcid.org/0000-0003-3832-8274)
- Bikash Panthi
- Michael A. Davies (ORCID: https://orcid.org/0000-0002-0977-0912)
- S. Prabhu
- Martin C. Tom (ORCID: https://orcid.org/0000-0002-2757-8641)
- Eric A. Goethe (ORCID: https://orcid.org/0000-0002-4151-2059)
- Thomas Hendrix Beckham (ORCID: https://orcid.org/0000-0001-6189-6996)
- Subha Perni (ORCID: https://orcid.org/0000-0003-2851-4903)
- J. Weinberg
- Chenyang Wang (ORCID: https://orcid.org/0000-0001-6798-0857)
- Diana Kaya (ORCID: https://orcid.org/0000-0002-6494-855X)
- Todd A. Swanson
- Denái R. Milton
- Hussein A Tawbi
- Caroline Chung
- Jing Li
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- Baylor College of Medicine (US)
- The University of Texas Health Science Center (US)
Publication Details
- Journal
- Neuro-Oncology Advances
- Published
- 2026-01-01
- DOI
- https://doi.org/10.1093/noajnl/vdaf276
- Primary Topic
- Brain Metastases and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00